We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
- Authors
Reck, M; von Pawel, J; Zatloukal, P; Ramlau, R; Gorbounova, V; Hirsh, V; Leighl, N; Mezger, J; Archer, V; Moore, N; Manegold, C; BO17704 Study Group
- Abstract
Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 9, p1804
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdq020